Psoriasis - Pipeline Insight, 2021
![](/report_cover/8047/psoriasis-pipeline-insight-2021_en.gif)
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “Psoriasis - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Psoriasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Psoriasis: Overview
Psoriasis is a chronic inflammatory skin disorder that is accompanied with various clinical manifestations and is caused due to the involvement of genetic, environmental, and immunological factors (Rendon & Schдkel, 2019). It is a non-contagious dermatosis disease affecting almost 2% of the world population. It can be observed in the form of recurring red and scaly skin plaques that can be prominently differentiated from the normal adjacent skin. The physical and psychological impact of psoriasis can be well-compared with those of diabetes, depression, heart disease and cancer. The percentage of body affected by psoriasis can vary on an individual basis. It is possible to observe mild (<2%), moderate (2–10%), and severe (>10%) psoriasis in different people, however the most commonly witnessed psoriasis is chronic plaque psoriasis or psoriasis vulgaris. It is a chronic inflammatory skin disorder in which the dendritic cells, T lymphocytes, macrophages, neutrophils, and keratinocytes lead to skin lesions.
'Psoriasis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Psoriasis pipeline landscape is provided which includes the disease overview and Psoriasis treatment guidelines. The assessment part of the report embraces, in depth Psoriasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Psoriasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Psoriasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Psoriasis Emerging Drugs
Further product details are provided in the repor
Psoriasis: Therapeutic Assessment
This segment of the report provides insights about the different Psoriasis drugs segregated based on following parameters that define the scope of the report, such as:
Psoriasis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Psoriasis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Psoriasis drugs.
Psoriasis Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Psoriasis - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Psoriasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Psoriasis: Overview
Psoriasis is a chronic inflammatory skin disorder that is accompanied with various clinical manifestations and is caused due to the involvement of genetic, environmental, and immunological factors (Rendon & Schдkel, 2019). It is a non-contagious dermatosis disease affecting almost 2% of the world population. It can be observed in the form of recurring red and scaly skin plaques that can be prominently differentiated from the normal adjacent skin. The physical and psychological impact of psoriasis can be well-compared with those of diabetes, depression, heart disease and cancer. The percentage of body affected by psoriasis can vary on an individual basis. It is possible to observe mild (<2%), moderate (2–10%), and severe (>10%) psoriasis in different people, however the most commonly witnessed psoriasis is chronic plaque psoriasis or psoriasis vulgaris. It is a chronic inflammatory skin disorder in which the dendritic cells, T lymphocytes, macrophages, neutrophils, and keratinocytes lead to skin lesions.
'Psoriasis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Psoriasis pipeline landscape is provided which includes the disease overview and Psoriasis treatment guidelines. The assessment part of the report embraces, in depth Psoriasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Psoriasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Psoriasis R&D. The therapies under development are focused on novel approaches to treat/improve Psoriasis.
This segment of the Psoriasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Psoriasis Emerging Drugs
- Bimekizumab: UCB
- ABP 654: Amgen
- MP1032: MetrioPharm
- Rimegepant: Biohaven Pharmaceuticals
- JTE-451: Akros Pharma
- GR-MD-02: Galectin Therapeutics
- ESR-114: Escalier Biosciences
Further product details are provided in the repor
Psoriasis: Therapeutic Assessment
This segment of the report provides insights about the different Psoriasis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Psoriasis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intramuscular
- Transdermal
- Topical.
- Intravenous
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Psoriasis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Psoriasis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Psoriasis drugs.
Psoriasis Report Insights
- Psoriasis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Psoriasis drugs?
- How many Psoriasis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Psoriasis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Psoriasis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Psoriasis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Arcutis Biotherapeutics
- Sinocelltech Ltd.
- FYB202 GmbH & Co. KG
- Celltrion
- Coherus BioSciences
- Janssen Pharmaceuticals
- Can-Fite Biopharma
- Arcutis Biotherapeutics, Inc.
- Amgen
- GlaxoSmithKline
- Galectin Therapeutics Inc.
- Evelo Biosciences, Inc.
- Galderma R&D
- BioMimetix JV, LLC
- Boehringer Ingelheim
- Aurigene Discovery Technologies Limited
- AnaptysBio, Inc.
- AmDerma
- Akeso
- Affibody
- Menlo Therapeutics Inc.
- Aristea Therapeutics
- UNION Therapeutics
- MetrioPharm AG
- Provectus Pharmaceuticals
- Sienna Biopharmaceuticals
- Santalis Pharmaceuticals
- Atridia Pty Ltd.
- Dr. Reddy's Laboratories Limited
- Galderma R&D
- AB Science
- Lycera Corp.
- LEO Pharma
- Kadmon Corporation, LLC
- Akros Pharma Inc.
- Athenex
- DelArrivo
- Theramab LLC
- AbbVie
- AstraZeneca
- Immunic
- Bio-Thera Solutions
- CSL Behring
- Palobiofarma
- SFA Therapeutics
- NeuClone
- Galapagos NV
- Boston Pharmaceuticals
- Cellenkos
- Sareum
- Temisis Therapeutics
- Dice Molecules
- Aclaris Pharma
- Midatech Pharma
- Xbrane Biopharma
- Roflumilast
- SCT630
- FYB202
- CT-P43
- CHS-1420
- Guselkumab
- Piclidenoson
- ARQ-154
- ABP 654
- GSK2982772
- GR-MD-02
- EDP1815
- CD10367
- BMX-010
- BI 730357
- AUR 101
- AM001
- AK101
- ABY-035
- Serlopitant
- RIST4721
- UNI-50001
- MP1032
- UHE-105
- Topical Rose Bengal
- SNA-120
- SAN021
- SHR-1314
- PPC-06
- PF-07038124
- NP000888
- Masitinib
- LYC-30937-EC
- LEO 22811
- KD025
- JTE-451
- Tirbanibulin
- DLX105-DMP
- TAB08
- ABBV-157
- AZD0284
- AK111
- IMU 935
- BAT2206
- CSL324
- PBF-1650
- SFA 002
- NeuLara
- GLPG3970
- BOS-475
- CK 0801
- SDC 1801
- TEM1657
- MTX114
- ATI-2138
- Xcimbane
Introduction
Executive Summary
Psoriasis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Psoriasis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Psoriasis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Psoriasis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
Comparative Analysis
Bimekizumab: UCB
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
MP1032: MetrioPharm
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
ESR-114: Escalier Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
ATI-2138: Aclaris Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Psoriasis Key Companies
Psoriasis Key Products
Psoriasis- Unmet Needs
Psoriasis- Market Drivers and Barriers
Psoriasis- Future Perspectives and Conclusion
Psoriasis Analyst Views
Psoriasis Key Companies
Appendix
Executive Summary
Psoriasis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Psoriasis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Psoriasis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Psoriasis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
Comparative Analysis
Bimekizumab: UCB
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
MP1032: MetrioPharm
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
ESR-114: Escalier Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
ATI-2138: Aclaris Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Psoriasis Key Companies
Psoriasis Key Products
Psoriasis- Unmet Needs
Psoriasis- Market Drivers and Barriers
Psoriasis- Future Perspectives and Conclusion
Psoriasis Analyst Views
Psoriasis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Psoriasis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Psoriasis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Psoriasis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Psoriasis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products